Abstract
Purpose: HMGI-C (High Mobility Group
protein Isoform I-C) protein is a member of the
high-mobility group AT-hook (HMGA) family of small non-histone chromosomal
protein that can modulate transcription of an ample number of genes.
Genome-wide studies revealed up regulation of the HMGI-C gene in many human
cancers. We suggested that HMGI-C might play a critical role in the progression
and migration of various tumors. However, the exact role of HMGI-C in breast
adenocarcinoma has not been cleared.
Methods: The cells were
transfected with siRNAs using transfection reagent. Relative HMGI-C mRNA and
protein levels were measured by quantitative real-time PCR and Western
blotting, respectively. The cytotoxic effects of HMGI-C
siRNA, Paclitaxel alone and combination on breast adenocarcinoma cells were
determined using MTT assay. The migration after treatment by HMGI-C siRNA,
Paclitaxel alone and combination were detected by wound-healing respectively.
Results: HMGI-C
siRNA significantly reduced both mRNA and protein expression levels in a 48
hours after transfection and dose dependent manner. We observed that the
knockdown of HMGI-C led to the significant reduced cell viability and inhibited
cells migration in MDA-MB-468 cells in vitro.
Conclusion: These results propose that HMGI-C silencing and Paclitaxel treatment alone can
inhibit the proliferation and migration significantly, furthermore, synergic
effect of HMGI-C siRNA
and Paclitaxel showed higher inhibition compared to mono treatment. Taken
together, HMGI-C could be used as a promising therapeutic agent in the
treatment of human breast adenocarcinoma. Therefore HMGI-C siRNA may be an
effective adjuvant in human breast adenocarcinoma.